Catalyst
Slingshot members are tracking this event:
Recro Pharma Reports Positive Top-Line Results from Pivotal Phase III Clinical Trial of IV Meloxicam
Do you think this event is important to the companies below? How will it affect their stock price?
Related Companies | Importance
|
Impact on Stocks
|
||||
---|---|---|---|---|---|---|
REPH |
|
|
Additional Information
The safety results demonstrated that IV meloxicam was well tolerated with no serious adverse events or bleeding events in the IV meloxicam-treated patients. The most common (≥3%) adverse events (AEs) were nausea, headache, pruritus, constipation vomiting, dizziness, flushing and somnolence, and were comparable to the placebo group. The IV meloxicam-treated patients experienced injection site pain and injection site erythema at a rate comparable to placebo. The majority of treatment emergent AEs (TEAEs) were mild in nature and there were no discontinuations due to AEs. There were no meaningful differences between treatment groups in vital signs, ECGs or clinical lab assessments.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jul 26, 2016
Related Projects
- With another successful trial for Meloxicam in post operative pain, where could the drug fit into the treatment landscape? REPH, INSY Executed On: Dec 02, 2016 at 10:30 AM EST
Related Keywords
Iv Meloxicam, Phase Iii, N1539, Summed Pain Intensity Difference